Fluconazole (Diflucan) Monitoring Parameters
- LFTs
- serum creatinine/BUN: baseline
Chemical Structure For: Fluconazole
References
Full list
. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508-9.
. Wells PS, Holbrook AM, Crowther NR et al. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
. Havlir DV, Dube MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
. Trapnell CB, Narang PK, Li R et al. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
. Narang PK, Trapnell CB, Schoenfelder JR et al. Fluconazole and enhanced effect of rifabutin prophylaxis. N Engl J Med 1994;330:1316-7.
. US Department of Health and Human Services (DHHS) and National Institutes of Health (NIH). The Living Document: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Retrieved October 6, 2005. Available on the World Wide Web at http://www.aidsinfo.nih.gov.
. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998;87:190-4.
. Niemi M, Neuvonen M, Juntti-Patinen L, et al. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther 2003;74:25-31.
. Henman A. Guarana (Paullinia cupana var. sorbilis): ecological and social perspectives on an economic plant of the central Amazon basin. J Ethnopharmacol 1982;6:311-38.
. Inspra™ (eplerenone) package insert. New York, NY: G.D. Searle LLC; 2003 Oct.
. Hansten PD, Horn JR. Cytochrome P450 Enzymes and Drug Interactions, Table of Cytochrome P450 Substrates, Inhibitors, Inducers and P-glycoprotein and footnotes. In: The Top 100 Drug Interactions - A guide to Patient Management. 2005 Edition. Edmonds, WA: H&H Publications; 2005:157-170.
. Targretin® (bexarotene capsules) package insert. San Diego CA: Ligand Pharmaceuticals Inc.; 2003 April.
. Targretin® gel (bexarotene gel) package insert. San Diego CA: Ligand Pharmaceuticals Inc.; 2002 Feb.
. VFEND® (voriconazole) package insert. New York,NY: Pfizer Inc; 2005 Mar.
. Tikosyn™ (dofetilide) package insert. New York, NY: Pfizer Labs; 1999 Dec.
. Gleevec® (imatinib mesylate) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004 Jan.
. Iressa® (gefitinib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003 May.
. Migranal® (dihydroergotamine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002 Jul.
. Retrovir® (zidovudine) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 Nov.
. Celebrex® (celecoxib) package insert. Chicago, IL: GD Searle LLC; 2005 Feb.
. Orlaam® (levomethadyl) package insert. Columbus, OH: Roxane Laboratories,Inc.; 2000 Jan. NOTE: In August 2003, levomethadyl was voluntarily removed from the US market due to cited reasons such as decreasing sales, safety concerns and the availability of other options for the management of opiate dependance.
. Methadone Hydrochloride Injection package insert. Wilmington, NC: AAI Pharma; 2004 Feb.
. Lotronex® (alosetron) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2003 Dec.
. Velcade® (bortezomib) package insert. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2004 Apr.
. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000;18:227-9.
. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol.1999;19:149-54.
. Pletal® (cilostazol) package insert. Tokushima, Japan: Otsuka Pharmaceutical Co., Ltd.; 2004 Feb.
. Viramune® (nevirapine) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2004 Jan.
. Tracleer® (bosentan) package insert. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2004 Nov.
. Reminyl® (galantamine) package insert. Titusville, NJ: Janssen Pharmaceutica Products, L.P.; 2003 Mar.
. Orap® (pimozide) package insert. Sellersville, PA: Teva Pharmaceuticals USA; 1999 Aug.
. Evoxac® (cevimeline) package insert. Montvale, NJ: Daiichi Pharmaceutical Corporation; 2002 Nov.
. Provigil® (modafinil) package insert. West Chester, PA: Cephalon, Inc; 2004 Feb.
. Suboxone® (buprenorphine and naloxone)/Subutex® (buprenorphine) package insert. Richmond, VA: Reckitt Benckiser Pharmaceuticals, Inc.; 2002 Oct.
. Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther 1999;24:347-55.
. Mevacor® (lovastatin) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2005 Apr.
. Zocor® (simvastatin) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2005 Aug.
. Rapamune® (sirolimus) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2005 Jul.
. Prograf® (tacrolimus) package insert. Deerfield, IL: Fujisawa Healthcare, Inc.; 2004 Mar.
. Diflucan® (fluconazole) package insert. New York, NY. Pfizer; 2004 Aug.
. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 1998;18:83-97.
. Dilantin® Kapseals® (extended phenyotin sodium capsules, USP) package insert. Morris Plains, NJ: Parke Davis; 1999 Aug.
. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370.
. Zonegran® (zonisamide) package insert. San Diego, CA: Elan Biopharmaceuticals; 2003 Aug.
. Cafergot® (caffeine; ergotamine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002 June.
. D.H.E. 45® (dihydroergotamine mesylate) package insert. Stein, Switzerland: Novartis Pharmaceuticals AG; 2002 Sep.
. Sansert® (methysergide) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2000 Nov.
. Chirocaine® (levobupivacaine) package insert. Stamford, CT: Purdue Pharma L.P.; 2001 Nov.
. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70.
. Koks C, Crommentuyn K, Hoetelmans R, et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001 Jun;51:631-5.
. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000;38:111-180.
. Wang JJ, Lee CL, Pan TM. Improvement of monacolin K, gama-aminobutyric acid and citrinin production ratio as a function of environmental conditions of Monascus purpureus NTU 601. J Ind Microbiol Biotechnol 2003;30:669-76.
. Sandimmune® (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002 Mar.
. Gilbert RE, Cooper ME, Krum H. Drug Administration in Patients with Diabetes Mellitus, Safety Considerations. Drug Safety 1998;18:441-55.
. Bextra® (valdecoxib) package insert. New York, NY: G.D. Searle LLC; 2004 Nov.
. Fentanyl citrate injection, USP package insert. North Chicago, IL: Abbott Laboratories; 1999 Apr.
. Mitscher LA, Jung M, Shankel D, et al. Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Med Res Rev 1997;17:327-65.
. Versed® (midazolam) package insert. Nutley, NJ: Roche Laboratories, Inc.; 1998 Dec.
. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53.
. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995;39:1907-12.
. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8.
. Odds FC. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia. Clin Infect Dis 2003;36:1229-31.
. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000:38(3):225-242.
. Cobb MN, Desai J, Brown LS Jr, et al. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998;63:655-62.
. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002:41:1153-1193.
. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12:S327-33.
. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994;169:1103-7.
. Hectorol® (doxercalciferol) package insert. Middleton, WI: Bone Care International, Inc.; 2005 Jun.
. Bennett JE. Antimicrobial agents: antifungal agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman’s the pharmacological basis of therapeutics, 9th edn. New York: McGraw Hill, 1996;1175-90.
. Prosom(R) (estazolam) tablets package insert. North Chicago, IL: Abbott Laboratories; 2004 Jan.
. Emend® (aprepitant) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2004 Dec.
. Darifenacin (Enablex®) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004 Dec.
. Hansten PD, Horn JR. Top 100 Drug Interactions Monographs. In: The Top 100 Drug Interactions - A guide to Patient Management. 2004 Edition. Edmonds, WA: H&H Publications; 2004:4-142.
. Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001;40:605-14.
. Zemplar® (paricalcitol capsules) package insert. North Chicago, IL: Abbott Laboratories; 2005 May.
. Abilify™ (aripiprazole) package insert. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2005 June.
. Rozerem™ (ramelteon) package insert. Lincolnshire, IL: Takeda Pharmaceuticals; 2005 Aug.
. Rhinocort® Aqua™ (budesonide) nasal spray package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2001.
. Powderly WG, Finkelstein DM, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993;118:495-503.
. Laine L, Dretler RH, Conteas CN et al. Fluconazole compared with ketoconazole for the treatment of candida esophagitis in AIDS. Ann Intern Med 1992;117:655-60.
. Sobel JD et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995;172:1263-8.
. Stevens DA. Coccidioidomycosis. N Engl J Med 1995;332:1077-82.
. Anaissie EJ et al. Management of invasive candidal infections: result of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
. Manfredi R, Mastroianni A, Coronado OV et al. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997;157:64-9.
. Centers for Disease Control and Prevention (CDC). The Living Document: USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Retrieved November 28, 2001. Available on the World Wide Web at http://www.hivatis.org.
. Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med 1997;126:689-96.
. Leen CLS, Dunbar EM, Ellis ME et al. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex. J Inf 1990;21:55-60.
. Esposito R, Castagna A, Foppa CU. Maintenance therapy of oropharyngeal candidiasis in HIV-infected patients with fluconazole. AIDS 1990;4:1033-4.
. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993;24:362-79.
. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83.
. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother December 8, 2005. Epub ahead of print, doi:10.1093/jac/dki440.
Related entries
Syndicate
|
